News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Micro-Sphere Release: CDMO To Invest €19 Million In GMP Facility Expansion



8/22/2017 2:24:10 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Spray drying specialist and capsule filling service provider Micro-Sphere is investing 21 million CHF (€19 million) into expanding its GMP manufacturing capabilities at its facility in Switzerland.

The investment, which is in response to increased market for spray drying and capsule filling for dry powder inhalers, will provide the contract development and manufacturing organisation (CDMO) with greater capacity to handle larger quantities of pharmaceutical powders and commercial volumes of finished dosage forms.

The expanded facility, which will see the GMP production area triple in size, will be home to some of the world’s leading spray drying and capsule filling technologies, which will be operational by Q4 2017.

Micro-Sphere founder and president of the Board, Dr. Michele Müller, said: “Both GMP spray drying as a particle engineering technique and low dose capsule filling are becoming increasingly popular across the market and at present there are very few CDMOs offering this level of capability, especially with our level of niche expertise.

“From our expanded facility, we will continue to produce both clinical and commercial products, with a particular specialism in dry powder inhalers. We look forward to unveiling the technologies we will be adding to our facility in the coming months and what I can promise is it will be some of the finest equipment in the world.”

From its GMP, SwissMedic and FDA approved facility near Lugano, Ticino, Micro-Sphere’s expert team supports customers in the US, Europe, New Zealand and Asia with spray drying capabilities for the development and manufacture of both potent and non-potent pharmaceutical products, with a particular focus on inhalable dosage forms.

-ENDS-

For further information, images and interview opportunities with Micro-Sphere, please contact Lindsay Baldry at ramarketing | lindsay@ramarketingpr.com | +44 (0)191 222 1242| www.ramarketingpr.com | www.twitter.com/ramarketingpr

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES